Received Feb 17, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEPAB | HEP A + HEP B (TWINRIX) | GLAXOSMITHKLINE BIOLOGICALS | 3 | 2553 | — |
given a third dose of TWINRIX too close together to second dose; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of drug dose administration interval too short in a 30-year-old male patient who received HAB (Twinrix) (batch number 2553, expiry date 25-SEP-2026) for prophylaxis. Previously administered products included Twinrix (received 1st dose on an unknown date). Concomitant products included Hepatitis a vaccine inact, Hepatitis b vaccine rHBsAg (yeast) (Twinrix). On 09-SEP-2024, the patient received the 3rd dose of Twinrix. On 09-SEP-2024, an unknown time after receiving Twinrix, the patient experienced drug dose administration interval too short (Verbatim: given a third dose of TWINRIX too close together to second dose). The outcome of the drug dose administration interval too short was unknown. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 24-JAN-2025 The pharmacist reported that a patient was given a third dose of Twinrix too close together to second dose (one month apart), which led to drug dose administration interval too short. The vaccination date, vaccine detail and patient demographics were obtained during this call. No further information was provided from the pharmacist´s end. The vaccine administration facility was the same as primary reporter.
TWINRIX